Zydus Lifesci.

Is Zydus Lifesci. overvalued or undervalued?

As of May 20, 2025, Zydus Lifesciences is considered undervalued and attractive with a PE ratio of 20.61, outperforming peers like Sun Pharma and Divi's Lab, and demonstrating strong long-term growth despite recent underperformance against the Sensex.

As of 20 May 2025, the valuation grade for Zydus Lifesciences has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company is currently assessed as undervalued, supported by a PE ratio of 20.61, an EV to EBITDA ratio of 13.04, and a PEG ratio of 0.92, which suggests that the stock is priced favorably relative to its growth potential.<BR><BR>In comparison to its peers, Zydus Lifesciences stands out as attractive against Sun Pharma, which is considered expensive with a PE ratio of 35.25, and Divi's Lab, which is very expensive at a PE ratio of 79.33. Additionally, Zydus has a higher ROCE of 31.73% compared to Cipla's 22.99%, reinforcing its strong operational efficiency. While the stock has underperformed the Sensex over the past year, it has shown significant gains over a three and five-year period, indicating a robust long-term growth trajectory.

Who are the top shareholders of the Zydus Lifesci.?

The top shareholders of Zydus Lifesci include the Zydus Family Trust with 74.96%, mutual funds at 6.36%, foreign institutional investors at 7.32%, and the Life Insurance Corporation of India at 3.85%, while individual investors hold about 5.41%.

The top shareholders of Zydus Lifesci include the Zydus Family Trust, which holds the highest stake at 74.96%. Other significant shareholders are mutual funds, which collectively hold 6.36%, and foreign institutional investors (FIIs), with a combined holding of 7.32%. The highest public shareholder is the Life Insurance Corporation of India, owning 3.85%. Additionally, individual investors hold about 5.41% of the company.

Who are in the management team of Zydus Lifesci.?

As of March 2022, the management team of Zydus Lifesci includes Chairman Pankaj R Patel, Managing Director Sharvil P Patel, and several independent directors, along with executive and compliance roles, ensuring effective governance and strategic direction.

As of March 2022, the management team of Zydus Lifesci includes the following individuals:<BR><BR>1. **Pankaj R Patel** - Chairman (Non-Executive)<BR>2. **Sharvil P Patel** - Managing Director<BR>3. **Mukesh M Patel** - Director<BR>4. **Nitin Raojibhai Desai** - Independent Director<BR>5. **Dharmishta N Rawal** - Independent Director<BR>6. **Apurva S Diwanji** - Independent Director<BR>7. **Ganesh N Nayak** - Executive Director<BR>8. **Bhadresh K Shah** - Independent Director<BR>9. **Dhaval N Soni** - Company Secretary & Compliance Officer<BR>10. **Akhil A. Monappa** - Independent Director<BR>11. **Upasana Konidela** - Independent Director<BR><BR>This team comprises a mix of executive and independent directors, contributing to the governance and strategic direction of the company.

What is the bonus history of the Zydus Lifesci.?

Zydus Lifesciences Ltd has issued bonuses in the past, with the most recent being a 1:2 bonus on April 5, 2010, and a 1:1 bonus on August 30, 2006. These actions reflect the company's commitment to enhancing shareholder value.

Zydus Lifesciences Ltd has a history of issuing bonuses. The most recent bonus was a 1:2 bonus issue, which was announced with an ex-date of April 5, 2010, and the record date was April 6, 2010. Prior to that, the company issued a 1:1 bonus on August 30, 2006, with a record date of August 31, 2006. This indicates that Zydus Lifesciences has engaged in bonus issues to enhance shareholder value in the past.

Has Zydus Lifesci. declared dividend?

Yes, Zydus Lifesciences Ltd has declared a 300% dividend, amounting to ₹3 per share, with an ex-date of July 26, 2024. While recent short-term returns have been negative, the company has shown strong total returns over the longer term.

Zydus Lifesciences Ltd has declared a 300% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 300%<BR>- Amount per share: 3 per share<BR>- Ex-date: 26 Jul 24<BR><BR>Dividend Yield: 0.31%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -3.75%, the dividend return was 0%, resulting in a total return of -3.75%.<BR><BR>Over the past year, the price return was -8.24%, the dividend return was 0.28%, leading to a total return of -7.96%.<BR><BR>In the 2-year period, the price return was 85.73%, the dividend return was 1.62%, culminating in a total return of 87.35%.<BR><BR>For the 3-year period, the price return was 162.57%, the dividend return was 3.36%, resulting in a total return of 165.93%.<BR><BR>In the last 4 years, the price return was 50.47%, the dividend return was 2.34%, which led to a total return of 52.81%.<BR><BR>Over the past 5 years, the price return was 166.74%, the dividend return was 4.13%, resulting in a total return of 170.87%.<BR><BR>Overall, Zydus Lifesciences Ltd has declared a substantial dividend, which contributes positively to its long-term total returns, especially over the 2, 3, 4, and 5-year periods. However, the recent short-term returns indicate some volatility, with negative performance in the last year and six months.

Who are the peers of the Zydus Lifesci.?

Zydus Lifesci.'s peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Lupin, Aurobindo Pharma, Abbott India, Alkem Lab, and GlaxoSmithKline Pharma. Zydus Lifesci. has good management risk and growth, but its 1-year return is -9.94%, the lowest among its peers.

Peers: The peers of Zydus Lifesci. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Lupin, Aurobindo Pharma, Abbott India, Alkem Lab, and Glaxosmi. Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Aurobindo Pharma, Abbott India, Alkem Lab, and the rest. Good management risk is found at Zydus Lifesci., Divi's Lab., Torrent Pharma, and Lupin. Average management risk is noted at Lupin. Growth is excellent at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Zydus Lifesci., and Lupin, while below average growth is seen at Divi's Lab., Torrent Pharma, Aurobindo Pharma, and Alkem Lab. Excellent capital structure is present in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Zydus Lifesci., Aurobindo Pharma, Abbott India, and Alkem Lab, while good capital structure is found at Torrent Pharma and Lupin.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Zydus Lifesci. has the lowest at -9.94%. Zydus Lifesci.'s return is significantly lower than the highest peer. Additionally, the peers with negative six-month returns include Zydus Lifesci., Lupin, Aurobindo Pharma, and Alkem Lab.

What does Zydus Lifesci. do?

Zydus Lifesciences Ltd is a major Indian pharmaceutical and biotechnology company, formerly known as Cadila Healthcare, with recent net sales of ₹65,279 Cr and a net profit of ₹11,709 Cr for Q1 2025. It has a market cap of ₹97,363 Cr and key metrics include a P/E ratio of 21.00 and a dividend yield of 0.31%.

Overview:<BR>Zydus Lifesciences Ltd is a leading innovation-driven pharmaceutical company in India, operating within the Pharmaceuticals & Biotechnology industry and classified as a Large Cap entity.<BR><BR>History:<BR>Zydus Lifesciences Ltd was formerly known as Cadila Healthcare Limited. The company is currently reporting its financial results for the quarter ending March 2025, with net sales and profit figures available for this period.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 65,279 Cr (Quarterly Results - Mar 2025)<BR>Most recent Net Profit: 11,709 Cr (Quarterly Results - Mar 2025)<BR>Market-cap value: INR 97,363 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 21.00<BR>Industry P/E: 37<BR>Dividend Yield: 0.31%<BR>Debt-Equity: -0.19<BR>Return on Equity: 19.58%<BR>Price to Book: 4.06<BR><BR>Contact Details:<BR>Address: Zydus Corporate Park S No 536, Khoraj Sarkhej-Gandhinagar H/W Ahmedabad Gujarat : 382481<BR>Tel: 91-079-26868100<BR>Email: upen.shah@zyduscadila.com<BR>Website: http://www.zyduscadila.com

How big is Zydus Lifesci.?

As of 24th July, Zydus Lifesciences Ltd has a market capitalization of 97,006.00 Cr, with recent Net Sales of 23,241.50 Cr and a Net Profit of 4,525.50 Cr.

As of 24th July, Zydus Lifesciences Ltd has a market capitalization of 97,006.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, Zydus Lifesciences reported Net Sales of 23,241.50 Cr and a Net Profit of 4,525.50 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 23,953.10 Cr and Total Assets totaling 34,857.90 Cr.

How has been the historical performance of Zydus Lifesci.?

Zydus Lifesci has shown consistent growth in net sales and profits, with net sales increasing from ₹14,253.10 Cr in March 2020 to ₹23,241.50 Cr in March 2025, and profit after tax rising from ₹1,175.60 Cr to ₹4,614.80 Cr during the same period, indicating strong financial performance and operational efficiency.

Answer:<BR>The historical performance of Zydus Lifesci shows a consistent growth trend in net sales and profits over the years, with significant increases noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Zydus Lifesci's net sales have risen from 14,253.10 Cr in March 2020 to 23,241.50 Cr in March 2025, reflecting a strong upward trajectory. The total operating income has followed a similar pattern, increasing from 14,253.10 Cr in March 2020 to 23,241.50 Cr in March 2025. The operating profit (PBDIT) has also improved significantly, growing from 2,897.30 Cr in March 2020 to 7,328.00 Cr in March 2025, indicating enhanced operational efficiency. Profit before tax has surged from 1,495.40 Cr in March 2020 to 6,026.70 Cr in March 2025, while profit after tax has increased from 1,175.60 Cr to 4,614.80 Cr during the same period. The earnings per share have more than tripled, rising from 11.49 in March 2020 to 44.99 in March 2025. On the balance sheet, total assets have grown from 22,833.70 Cr in March 2020 to 34,857.90 Cr in March 2025, while total liabilities have decreased from 7,901.10 Cr to 0.00 Cr, showcasing a strong financial position. Cash flow from operating activities has also improved, increasing from 2,931.00 Cr in March 2020 to 6,776.00 Cr in March 2025, contributing to a positive net cash inflow in the latest fiscal year. Overall, Zydus Lifesci has demonstrated robust growth across key financial metrics over the past several years.

Is Zydus Lifesci. technically bullish or bearish?

As of December 1, 2025, Zydus Lifesci. has shifted to a mildly bearish trend, indicated by bearish signals in the MACD and Bollinger Bands, despite some mildly bullish daily moving averages.

As of 1 December 2025, the technical trend for Zydus Lifesci. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by bearish signals in the MACD and Bollinger Bands on both weekly and monthly time frames. The KST also indicates a mildly bearish trend. The daily moving averages show a mildly bullish signal, but this is overshadowed by the overall bearish indicators. The RSI shows no signal, and Dow Theory indicates no trend in both weekly and monthly assessments. Overall, the strength of the bearish stance is supported by the prevailing trends across multiple indicators.

When is the next results date for Zydus Lifesciences Ltd?

The next results date for Zydus Lifesciences Ltd is February 9, 2026.

The next results date for Zydus Lifesciences Ltd is scheduled for February 9, 2026.

Are Zydus Lifesciences Ltd latest results good or bad?

Zydus Lifesciences Ltd's latest results show strong year-on-year growth with a 38.13% increase in net profit, but sequentially, net profit and sales declined, raising concerns about sustainability. Overall, the results are good in the long term but highlight volatility in the short term, prompting investors to watch for future stabilization.

Zydus Lifesciences Ltd's latest results present a mixed picture. On one hand, the company reported a strong year-on-year net profit growth of 38.13%, reaching ₹1,258.60 crores, and a net sales increase of 16.92% to ₹6,123.20 crores. These figures indicate operational efficiencies and effective cost management. Additionally, the operating margin improved significantly, reflecting the company's ability to enhance profitability through better operational practices.<BR><BR>However, there are notable concerns. The sequential performance showed a decline, with net profit down 14.19% and net sales down 6.85% compared to the previous quarter. This raises questions about the sustainability of the growth trajectory. The increase in interest expenses, which surged dramatically year-on-year, is also a significant concern as it impacts profitability.<BR><BR>Overall, while the company demonstrates strong long-term fundamentals and capital efficiency, the recent quarterly performance highlights volatility and challenges that could affect investor sentiment. Therefore, the results can be seen as good in terms of year-on-year growth but concerning when looking at the sequential trends. Investors may want to monitor upcoming quarters for signs of stabilization and recovery.

Should I buy, sell or hold Zydus Lifesciences Ltd?

Why is Zydus Lifesciences Ltd falling/rising?

As of 13-May, Zydus Lifesciences Ltd's stock price is rising due to strong fundamentals, including a 12.37% annual growth rate in net sales and a low debt-to-equity ratio of 0.05. The stock has outperformed its sector and shows impressive long-term returns, indicating solid financial health and ongoing investor interest.

As of 13-May, Zydus Lifesciences Ltd's stock price is rising, currently at 938.95, reflecting an increase of 8.2 points or 0.88%. This upward movement can be attributed to several factors. The stock has demonstrated strong long-term fundamental strength, evidenced by a healthy annual growth rate in net sales of 12.37% and an operating profit growth of 22.94%. Additionally, the company maintains a low debt-to-equity ratio of 0.05, indicating financial stability.<BR><BR>In terms of performance, Zydus Lifesciences has outperformed the sector today by 0.93%, and its returns over the past year stand at 4.07%, which is significantly better than the BSE500 index. The stock has also shown impressive returns over longer periods, with a 3-year return of 82.89%, compared to the Sensex's 20.28%. <BR><BR>Despite a recent decline in investor participation, with delivery volume falling by 25.72% against the 5-day average, the stock remains liquid enough for trading, indicating ongoing interest from investors. Furthermore, the company's return on equity (ROE) of 17.34% signifies high profitability, and its attractive valuation, with a PEG ratio of 1.3, suggests that it is trading at a fair value relative to its peers.<BR><BR>Overall, the combination of strong financial metrics, market-beating performance, and a solid growth outlook contributes to the rising stock price of Zydus Lifesciences Ltd.

Which are the latest news on Zydus Lifesci.?